Automated Cord Blood Processing:
|
|
- Benjamin Doyle
- 8 years ago
- Views:
Transcription
1 TM Automated Cord Blood Processing: A Follow-up to the Pilar Solves Study Comparing the AXP vs the Sepax Cord Blood Processing Systems CHRISTY KIM, PETRA CRAVENS, MINDY WILKE-DOUGLAS AND MITCHEL SIVILOTTI
2 Introduction Safe, efficient, and reliable production through automation is the key to standardizing CBU processing. Cord blood (CB) is a well-known and valuable source of progenitor cells, which can be used to treat disorders in the fields of oncology, hematology, and medical genetics that are currently most commonly treated with cells sourced from bone marrow (BM) and peripheral blood (PB). Though CB has many well-studied advantages over BM and PB, relative neutrophil and platelet engraftment times remain a challenge that does not easily offset the benefits provided by CB, which include the ease of procurement and reduced graft vs. host disease (GvHD) risk. In short, CB engraftment may take 2-3 times longer than BM, which could expose transplant recipients to an elongated and dangerous state of neutropenia. 1 The delay in engraftment is due, in part, to suboptimal cell counts within a single unit of CB, the main limitation of CB use. Therefore, the target of CB therapeutic clinical trials has been focusing on CB cell expansion 2-4. Due to this limitation, the industry has focused CB primarily for use in pediatric indications where cell counts meet the required dose/kg prescription or, in cases where acceptable BM donors are not available, a double CB transplant is conducted at considerable cost to the patient or local healthcare system. 5 The message, regardless of protocol The message... is the continued necessity to establish inventory of the highest possible number of potent progenitor cells from a given CB donor. type (direct transplantation vs. cell expansion), is the continued necessity to establish inventory of the highest possible number of potent progenitor cells from a given CB donor. In order to keep pace with transplantation demands and future therapeutic innovation, cord blood banks (CBBs) are driven to continually improve the quality and standards of their CB collection, processing, and storage protocols. An early example of this was the adoption of volume reduction techniques developed in 1995 by Rubinstein et al. which allowed for improved storage efficiency; cord blood units (CBUs) can be stored in a single BioArchive Cryopreservation Dewar spanning only 4 feet in diameter due both to the advanced dewar design and to the smaller freezing bag designs which brought the final cryopreserved volume of a CBU to 25 ml as an industry standard. Volume reduction of the final CBU also allowed for a reduction in the volume of DMSO used for cryopreservation which allowed transplant centers the option to infuse cells without additional cell washing, a step associated with the loss of important transplantable cells. 8 Moreover, volume reduction depletes red blood cells (RBCs) reducing the potential recipient s reaction to ABO incompatibility and improving stem cell functionality. 6,7 Initial protocols for volume reduction of CBUs involved manual processing using agents such as hydroxyethyl starch (HES) to facilitate RBC sedimentation by rouleaux formation. 8 However, both the use of HES and manual processing are increasingly viewed by some as suboptimal practices. The use of HES, for example, is not clinically PROPERTY OF CESCA THERAPEUTICS, INC [A] PAGE 2 OF 8
3 The Use of HES and Manual Processing The FDA and the PRAC both report risks associated with the use of HES products which include increased mortality and kidney injury in patients with sepsis, burn injuries, or critically ill patients. 13,14 approved or licensed in a number of countries including Canada, Portugal, and Japan: HES can be detected years after administration and safety concerns including severe pruritus, disseminated intravascular coagulopathy, and shock have led the field to search for alternative processing methods that do not incorporate the use of additives In addition, the United States Department of Health and Human Services Federal Agency s Food and Drug Administration (FDA) and the European Medicines Agency s Pharmacovigilance Risk Assessment Committee (PRAC) both report risks associated with the use of HES products which include increased mortality and kidney injury in patients with sepsis, burn injuries, or critically ill patients. 13,14 Manual processing of CBUs, typically performed using HES, can severely limit laboratory production efficiency, both temporally and economically, and further introduces user to user variability, making standardization and lean-manufacturing processes more challenging. The manual separation procedure relies on multiple technicians and technician-dependent technique, which requires comprehensive training to perfect and may walk out the door with the employee should they choose to change employment. Further, the manual process itself is relatively long and laborious due, in part, to a sedimentation step that can alone take up to 90 minutes. 15 PROPERTY OF CESCA THERAPEUTICS, INC [A] PAGE 3 OF 8
4 Results and Discussion Safe, efficient, and reliable production through automation is the key to standardizing CBU processing. Automation allows CBBs to implement lean manufacturing principles that drive consistency and quality across all CBUs and thus increases the likelihood of optimal inventories for clinical use. Presently, there are two leading automated systems for CBU processing with adequate published data available for analysis: the AXP system, part of the AutoXpress Platform (Thermogenesis ) of products offered by CESCA Therapeutics, and the Sepax system (Biosafe S.A.). Both systems volume reduce CBUs in a functionally closed approach to minimize contamination that can be introduced by other methods. Both automated systems reduce operator dependent variability and enable better standardization and reproducibility to ensure that the sample is banked under optimal conditions. Both systems are efficient in reducing processing times to around 30 minutes. The AXP and Sepax systems can be used with or without HES but the AXP system, typically used without HES, minimizes the risks and complications associated with potentially dangerous chemical additives while also reducing the cost of an added reagent. As automated systems, the AXP and Sepax systems can yield excellent recoveries that are comparable if not better than manual methods The AXP system consistently yields MNC recoveries greater than 90% when processing CBUs with an average range of ml without HES addition. 15,16 Cord Blood Registry (CBR), one of the world s largest and most experienced private cord blood banks, consistently obtains 95-99% recoveries for MNC and CD34+ populations using the AXP system in conjunction with lyophilized heparin. 16 Side by side, the Sepax and AXP systems without the use of HES have never accurately been compared in a single peer reviewed publication. An attempt was made by Pilar Solves et al. in a retrospective study, but this evaluated the Sepax system using HES and the AXP system without the use of HES, which is not a study where both technologies where studied under equal conditions. 18 While this study reported 2% more TNCs recovered with the Sepax system with the HES protocol, we can conclude that the AXP system without HES, was arguably equivalent and offers an additional advantage to the Sepax because it does not require HES to obtain these efficient recoveries. The AXP system without HES offers an additional advantage to the Sepax and Sepax II because it does not require HES to obtain efficient stem cell recoveries. PROPERTY OF CESCA THERAPEUTICS, INC [A] PAGE 4 OF 8
5 Results and Discussion (continued) Although most published data with the Sepax system includes the addition of HES, 17,18 there is a study from Zingsem et al. in 2003 reporting the performance of the Sepax system without HES. 19 To summarize, the Sepax system without the addition of HES volume reduced CBUs resulting in % MNC and % CD34+ recoveries. When compared to Takanshi et al. s data from 2010, these values are lower than the recovery performance with the AXP system, likewise without HES, ( % MNC and % CD34+ recoveries) as seen in Figure 1. 15,19 Additionally, the Sepax system without HES reduces RBCs by % compared to % as seen with the AXP system without HES (Figure 2). 15,19 When HES is added the Sepax system RBC depletes at comparable values to the AXP system without HES ( % and % respectively) (Figure 3). 18 Furthermore, in Solves et al. s study, the Sepax system and not the AXP system showed an inverse correlation between TNC recovery and RBC depletion (rho= , P=0.000). 18 This may be in part due to the inherent technological differences between both systems. The Sepax system starts with plasma extraction, followed by collection of the buffy coat to a defined volume before extracting RBCs to the RBC collection bag; 19 whereas, the AXP system is designed to remove the RBC fraction first to consistently deliver a defined volume of packed RBCs into the freezing bag followed by the buffy coat and then utilizes the plasma to achieve the desired final volume, thereby achieving consistent hematocrit levels regardless of CBU processed. Figure 1. Stem cell percentage recoveries (MNC and CD34+) for the AXP and Sepax systems both without HES. STEM CELL RECOVERIES WITHOUT HES % Recoveries MNC CD MNC CD34+ 0 AXP Takanashi et al. Sepax Zingsem et al. PROPERTY OF CESCA THERAPEUTICS, INC [A] PAGE 5 OF 8
6 Results and Discussion (continued) Figure 2: Red blood cell depletion percentage for the AXP and the Sepax systems both without HES. Figure 3: Red blood cell depletion percentage for the AXP system without HES and the Sepax system with HES. RBC DEPLETION WITHOUT HES RBC DEPLETION (PILAR SOLVES ET AL. 2013) 100 % RBC Depletion % RBC Depletion AXP Takanashi et al. Sepax Zingsem et al. 0 AXP Sepax (with HES) Summary In conclusion, the AXP system provides consistently high recoveries of TNC, MNC, and CD34+ cells without unnecessary exposure to HES to circumvent potentially serious adverse reactions in patients and does so while delivering consistently low RBC contamination, making it an attractive system for clinical applications. The trend in the restricted use of HES in subsets of patient populations and the ban of HES by some countries show the gravity of the risks outweighing the benefits worldwide. The AXP system s proprietary processing technology also consistently reduces RBC contamination to ensure maximal post-thaw progenitor recoveries while minimizing RBC secreted factors which can impair invasion and colony forming unit capacities of stem cells. 6,7 Maximizing cell counts, viabilities, and potencies in an automated manner are the key factors in building bank-worthy CBUs for therapies. With our ever-expanding technologies, CESCA Therapeutics (f.k.a. Thermogenesis Corp.) is working to bridge the gap between the number of CBUs banked and the number of CBUs used for transplantation. PROPERTY OF CESCA THERAPEUTICS, INC [A] PAGE 6 OF 8
7 REFERENCES 1. Rocha, V., et al. (2000). Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 342(25): Delaney, C., et al. (2010). Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 16(2): Bird, G. A., et al. (2014). Expansion of Human and Murine Hematopoietic Stem and Progenitor Cells Ex Vivo without Genetic Modification Using MYC and Bcl-2 Fusion Proteins. PLoS One 9(8): e Su, Y. H., et al. (2014). BMP-7 improved proliferation and hematopoietic reconstitution potential of ex vivo expanded cord blood-derived CD34 cells. Hum Cell. 5. Barker, J. N., et al. (2005). Transplantation of 2 partially HLAmatched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105(3): Querol S., et al. (2002). Effect of red blood cell content on progenitor function after cryopreservation of cord blood buffycoat products. Bone Marrow Transplant 29 (Suppl 2): S202 (poster 740). 7. Assmus, B., et al. (2010). Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 55(13): Rubinstein, P., et al. (1995). Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A 92(22): Trivedi, S. M., et al. (1984). Hydroxyethyl starch serum levels in leukapheresis donors measured by modified periodic acid-schiff staining technique. Transfusion 24(3): Szepfalusi, Z., et al. (1993). Human monocytes and keratinocytes in culture ingest hydroxyethylstarch. Arch Dermatol Res 285(3): Jurecka, W., et al. (1993). Hydroxyethylstarch deposits in human skin--a model for pruritus? Arch Dermatol Res 285(1-2): Chang, J. C., et al. (1990). Disseminated intravascular coagulation due to intravenous administration of hetastarch. Am J Med Sci 300(5): FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solution in some settings. ucm htm. 25 Nov Hydroxyethyl-starch solutions (HES) no longer to be used in patients with sepsis or burn injuries or in critically ill patients. medicines/human/referrals/hydroxyethyl_starchcontaining_solutions/human_referral_prac_ jsp&mid=wc0b01ac05805c516f. 19 Dec Takanashi, M., et al. (2010). Red blood cell depletion of cord blood using an automated system- Evaluation of the AXP system. Japanese Journal of Transfusion and Cell Therapy 56(1): Badowski, M. S. and D. T. Harris (2012). Collection, processing, and banking of umbilical cord blood stem cells for transplantation and regenerative medicine. Methods Mol Biol 879: Lapierre, V., et al. (2007). Cord blood volume reduction using an automated system (Sepax) vs. a semi-automated system (Optipress II) and a manual method (hydroxyethyl starch sedimentation) for routine cord blood banking: a comparative study. Cytotherapy 9(2): Solves, P., et al. (2013). Qualitative and quantitative cell recovery in umbilical cord blood processed by two automated devices in routine cord blood banking: a comparative study. Blood Transfus 11(3): Zingsem, J., et al. (2003). Cord blood processing with an automated and functionally closed system. Transfusion 43(6): PROPERTY OF CESCA THERAPEUTICS, INC [A] PAGE 7 OF 8
8 PROPERT Y OF CESCA THERAPEUTICS, INC [A] CESCA THERAPEUTICS INC Citrus Road Rancho Cordova, CA USA
Meta-Analysis of the AXP and Sepax Automated Cord Blood Processing Systems
TM Meta-Analysis of the AXP and Sepax Automated Cord Blood Processing Systems CHRISTY KIM, MINDY WILKE-DOUGLAS, AND MITCHEL SIVILOTTI Introduction Automation is the key to standardizing cord blood processing.
More informationPublic Cord Blood Banking at the National Cord Blood Program (NCBP)
Public Cord Blood Banking at the National Cord Blood Program (NCBP) A. Scaradavou, MD Medical Director, National Cord Blood Program, New York Blood Center Associate Attending, Pediatric BMT Memorial Sloan-Kettering
More informationPreparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between
Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program ISCT 2012 Disclosures: none The problem:
More informationUMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
More informationProcessing & Utilization of Cord Blood for Transplant
Processing & Utilization of Cord Blood for Transplant 2010-Jan Jan-15 Nicole L. Prokopishyn, PhD HPC Processing Laboratory Director Calgary Laboratory Services Overview Cord Blood Processing Pre-Freeze
More informationCord Blood: Thawing & Infusion Practical Methods
Cord Blood: Thawing & Infusion Practical Methods Donna M Regan, MT(ASCP)SBB St. Louis Cord Blood Bank @ SSM Cardinal Glennon Children s s Medical Center Objectives Present variety of product configurations
More informationOneMedForumSF 2012 Conference. January 10th
OneMedForumSF 2012 Conference January 10th Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by
More informationSepax. your child s cord blood is in safe hands. World leader in adult stem cell processing
Sepax your child s cord blood is in safe hands World leader in adult stem cell processing Biosafe Experience Credibility Innovation Dear Customer, Innovation in cell processing is our credo and this is
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationBeyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic
More informationA simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences
Cytotherapy (2001) Vol. 3, No. 6, 429 433 A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences JM Alonso III 1, DM Regan 1, CE
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationRecommendations to Transplant Centres Performing Cord Blood Transplants. Why Choosing the Right Thaw Method Could Save a Patient s Life
Recommendations to Transplant Centres Performing Cord Blood Transplants Vicki Antonenas Why Choosing the Right Thaw Method Could Save a Patient s Life Lynn O Donnell (USA) 1 The process of receiving, testing
More informationCORD BLOOD BANKING FAQ
CORD BLOOD BANKING FAQ Cord Blood & Stem Cells Q: What is umbilical cord blood (UCB)? A: Bone marrow, peripheral blood and UCB constitute the three primary sources of stem cells. Cord blood, which, until
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center April 30, 2014 Objectives Since
More informationDo you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma
1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationComparability of Cord Blood Units
Comparability of Cord Blood Units John D. McMannis,, Ph.D. Professor of Cancer Medicine Director, Cell Therapy Laboratory Technical Director, UT MDAnderson Cord Blood Bank Liaison Meeting, Bethesda June
More informationCPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD
The blood and marrow transplant field has 15 dedicated CPT codes. These CPT codes can be categorized into three groups: 1. Collection Codes 2. Cell Processing Codes 3. Cell Infusion Codes Collection Codes
More information4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and
More informationSibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program
Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program MARK C. WALTERS, LYNN QUIROLO, ELIZABETH T. TRACHTENBERG, SANDIE EDWARDS, LISA HALE, JOANNA
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center September 18, 2013 Objectives
More informationTechnical report High-efficiency volume reduction of cord blood using pentastarch
(2001) 27, 457 461 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Technical report High-efficiency volume reduction of cord blood using pentastarch H Yang 1,2,
More information5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationHow To Transplant Cord Blood
MP 7.01.38 Placental/Umbilical Cord Blood as a Source of Stem Cells Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationBioPreservation Today
BioPreservation Today Volume 1 - Issue 4 FALL 2009 published by BioLife Solutions, Inc. FEATURE ARTICLE CASE STUDY: MODIFIED CRYOPRESERVATION OF UMBILICAL CORD BLOOD STEM CELLS AT CRYOBANKS INTERNATIONAL
More informationAssureImmune. Cord Blood: For Something That Precious, Bank with the Best. Important Facts for When You re Expecting. AssureImmune.
AssureImmune AssureImmune Cord Blood: For Something That Precious, Bank with the Best Important Facts for When You re Expecting Banking your baby s umbilical cord blood could be a potentially lifesaving
More informationCord Blood Market Trends, circa 2014
GENReports: Market & Tech Analysis Cord Blood Market Trends, circa 2014 > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Topic Introduction and Scope The focus of this GEN
More informationBioArchive Freezing Curve for Cord Blood
BioArchive Freezing Curve for Cord Blood Determination of the Specific Freezing in the BioArchive System to Provide the Highest Viability of Cord Blood MNC as Measured by -C Assays Introduction Freezing
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationhematopoietic stem cells from cord blood: - costless but too expensive? Dr. Vincent Kindler Geneva Cord Blood Bank HUG vincent.kindler@hcuge.
hematopoietic stem cells from cord blood: - costless but too expensive? Dr. Vincent Kindler Geneva Cord Blood Bank HUG vincent.kindler@hcuge.ch Spring water: Manufactured by nature COSTLESS Cord Blood:
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationDiscover the Possibilities Born With Your Baby
Discover the Possibilities Born With Your Baby Your Simple Guide to Saving Cord Blood The Power and Promise The lifesaving power of cord blood and regenerative healing potential of cord blood and cord
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationGuidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution
More informationTransmedcon 2014. Ahmedabad, Gujarat November 14-16, 2014
FACT Accreditation for Cord Blood Banks and Cellular Therapy Nadim Mahmud, MD, PhD Associate Professor of Medicine Division of Hematology/Oncology Director, Hospital Stem Cell Laboratory Blood & Marrow
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationSo, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.
1 Who is the most influential figure in cord blood around the world? What do you think has been the biggest achievement within the cord blood sector? Which is the most important development in cord blood
More informationCanadian Blood Services National Public Cord Blood Bank
Canadian Blood Services National Public Cord Blood Bank Dr. Heidi Elmoazzen Director, National Public Cord Blood Bank Hematopoetic Stem Cells Hematopoetic stem cells are not yet mature (undifferentiated)
More informationNot All Stem Cells are the Same
Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationNatasha Kekre, 1 Jennifer Philippe, 2 Ranjeeta Mallick, 3 Susan Smith, 2 and David Allan 1,2,4. 1. Introduction
Hindawi Publishing Corporation Stem Cells International Volume 2013, Article ID 124834, 6 pages http://dx.doi.org/10.1155/2013/124834 Research Article Modelling Improvements in Cell Yield of Banked Umbilical
More informationEquine Stem Cells. Sources, Processing, Expansion, Storage and Shipping
Equine Stem Cells Sources, Processing, Expansion, Storage and Shipping Sean Owens, DVM, Diplomate ACVP Medical Director, UC Davis Veterinary Regenerative Medicine Laboratory What is a Stem Cell and What
More informationStem Cell Background Paper
Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,
More information14.0 Stem Cell Laboratory Services
Laboratory Services Contact Information: To inquire about assisting with surgical harvesting of bone marrow, cellular therapy (CT) product processing, cryopreservation, storage, or any other lab services,
More informationEnumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood
Application Note Primary Cell Analysis Enumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood Cell Viability Introduction: Bone Marrow, Cord Blood, Stem
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationCord Blood Re-imagined The use of cord blood stem cells for clinical applications and medical innovations
GE Healthcare Proceedings of the Symposium Cord Blood Re-imagined The use of cord blood stem cells for clinical applications and medical innovations 12 th Annual Meeting of the International Society for
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2015 Origination: 12/2001 Next Review: 12/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationHAEMOPHILIA & UMBILICAL CORD BLOOD TRANSPLANT
HAEMOPHILIA & UMBILICAL CORD BLOOD TRANSPLANT Haemostatic System in Body Blood vessels Platelets Plasma coagulation system Proteolytic or Fibrinolytic system How Bleeding Stops Vasoconstriction Platelet
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationStatement of Joanne Kurtzberg, M.D.
Statement of Joanne Kurtzberg, M.D. President of the Cord Blood Association Jerome Harris Distinguished Professor of Pediatrics and Pathology Chief Scientific Officer and Medical Director, Robertson Clinical
More informationSaving your baby s s cord blood: Is this good insurance?
Saving your baby s s cord blood: Is this good insurance? 32 th SEMINAR ON PERINATAL MEDICINE CONTROVERSIES IN PERINATAL MEDICINE: EVIDENCE FOR CURRENT PRACTICE Sante Fe, New Mexico Mervin C. Yoder, MD
More informationHematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low
Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults
More informationOverview of OneMatch, including the OneMatch Public Cord Blood Bank
Overview of OneMatch, including the OneMatch Public Cord Blood Bank Dr. Heidi Elmoazzen, Director OneMatch Public Cord Bank 2012-09-27 Outline Overview and Introduction Overview of the need for stem cells
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationCord Blood Bank Business Plan
Cord Blood Bank Business Plan A sample of how to create a new program Produced by the AABB subsection: Cellular Therapy Business Management with major contributions by Nicole Omer TABLE OF CONTENTS Page
More informationFlow cytometric analysis of stem cells derived from umbilical cord blood CD34+/CD45+ enumeration and viability
Flow cytometric analysis of stem cells derived from umbilical cord blood CD34+/CD45+ enumeration and viability Doretha Thompson Dissertation in fulfillment of the requirements for the degree Magister Scientiae
More informationEconomics of Cord Blood Banking. Michael Boo NMDP Be The Match September 11, 2015
Economics of Cord Blood Banking Michael Boo NMDP Be The Match September 11, 2015 Historical Use UCB Use Data 2 NMDP Historical Transplants by Product 7,000 6,500 6,000 5,500 5,000 4,500 4,000 3,500 3,000
More informationHow To Run A Cord Blood Bank
INTERNATIONAL STANDARDS FOR CORD BLOOD COLLECTION, BANKING, AND RELEASE FOR ADMINISTRATION ACCREDITATION MANUAL Fifth Edition DRAFT September 2012 NOTICE These Standards are designed to provide minimum
More informationThermoGenesis Corp. May 2012
ThermoGenesis Corp. May 2012 Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by the context
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationUmbilical Cord Blood Stem Cells Current Status & Future Potential
Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu
More informationCIGNA HEALTHCARE COVERAGE POSITION
CIGNA HEALTHCARE COVERAGE POSITION Subject Umbilical Cord Blood Banking Table of Contents Coverage Position... 1 General Background... 1 Coding/Billing Information... 3 References... 3 Revised Date...
More informationSTEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE
STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE What are Stem Cells? Stem cells are the basic building blocks of all the cells, tissues and organs in the human body. The role of the stem
More informationComplete 2015-16 Global Cord Blood Banking Industry Report BIOINFORMANT WORLDWIDE, LLC
TABLE OF CONTENTS I. Abstract.. p.11 II. Overview of Technical & Medical Characteristics of Cord Blood..p.16 A. Introduction to Cord Blood and Cord Tissue B. Definitions and Nomenclature C. Technical Advantages
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationCESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS
CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS Company Completes Year of Transformation, Makes Regulatory Advances in Clinical Programs RANCHO CORDOVA September 29, 2014 Cesca Therapeutics
More informationAn Introduction to Canada s National Public Cord Blood Bank
An Introduction to Canada s National Public Cord Blood Bank Dr. Heidi Elmoazzen Director, National Public Cord Blood Bank Hematopoetic Stem Cells Hematopoetic stem cells are not yet mature (undifferentiated)
More informationCord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral
More informationJennifer G. Collins, RN Children s Hospital of Chicago
Jennifer G. Collins, RN Children s Hospital of Chicago Review the importance of consultation with the stem cell transplant team Review criteria to begin harvest Review ways to modify a harvest procedure
More informationANTHONY NOLAN SEARCH ALGORITHM FOR A BASIC CORD BLOOD UNIT SELECTION BY SERGIO QUEROL AND IRINA EVSEEVA FEBRUARY 2012
ANTHONY NOLAN SEARCH ALGORITHM FOR A BASIC CORD BLOOD UNIT SELECTION BY SERGIO QUEROL AND IRINA EVSEEVA FEBRUARY 2012 PAGE 1 OF 7 PRINCIPLES FOR A NEW ALGORITHM Once cord blood transplantation (CBT) is
More informationReview. Cord blood as an alternative source of haemopoietic stem cells. J. Hows, A. Nicol, P. Denning-Kendall, C. Donaldson, M. Nieda & B.
Annals of Oncology 7 (Suppi 2): 47-51, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Review Cord blood as an alternative source of haemopoietic stem cells J. Hows, A. Nicol, P. Denning-Kendall,
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Umbilical Cord Blood Banking Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 3 References... 4 Effective Date... 6/15/2014
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationDirected/Related Cord Blood Collection by NHS Blood and Transplant
Directed/Related Cord Blood Collection by Jacqui Thompson Clinical Scientist Section Head of Specialist Procedures Stem Cells and Immunotherapies Department National Blood Service, NHSBT Birmingham Why
More informationCanadian Blood Services National Public Cord Blood Bank Give Life Twice Transfusion Medicine Residents
Canadian Blood Services National Public Cord Blood Bank Give Life Twice Transfusion Medicine Residents Eileen Quinlan Collection Supervisor, Brampton (GTA) 2015-11-10 History One Match Stem Cell and Marrow
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2014 Origination: 12/2001 Next Review: 12/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationCORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE
CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE Dennis M. Todd, Ph.D. The New Jersey Cord Blood Bank a Division of Bergen Community Regional Blood Center Montvale, NJ Hematopoietic Stem Cell Transplantation
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationThe Impact of Maternal, Neonatal and Collections factors on the TNC count of an Umbilical Cord Blood Donation
The Impact of Maternal, Neonatal and Collections factors on the TNC count of an Umbilical Cord Blood Donation By: NHS Cord Blood Bank (Colindale Laboratory) Date: 26 th September 2014 NHS insert Cord your
More informationUMBILICAL CORD BLOOD HARVESTING & STORAGE
Protocol: TRP009 Effective Date: October 14, 2013 UMBILICAL CORD BLOOD HARVESTING & STORAGE Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 BACKGROUND... 2 CLINICAL EVIDENCE...
More informationInternational NetCord Foundation Executive Committee Conference Call Minutes May 23, 2007
International NetCord Foundation Executive Committee Conference Call Minutes Committee Members: Board Members: Staff: President Joan Garcia and Drs. Yves Beguin and Elizabeth Shpall Drs. Cristina Navarrete
More information10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program. Thursday, June 7
10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program Thursday, June 7 7:00 8:00 AM Breakfast in Exhibit Hall Session IA 8:00 10:00 AM Advances in
More informationTABLE OF CONTENTS Complete 2015-16 Global Cord Blood Banking Industry Report (August 2015)
TABLE OF CONTENTS Complete 2015-16 Global Cord Blood Banking Industry Report (August 2015) I. Abstract.. p.12 II. Overview of Technical & Medical Characteristics of Cord Blood..p.17 A. Introduction to
More informationIn contrast to the very high transplant-related
Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated
More informationUMBILICAL CORD BLOOD, STEM CELL BANKING
UMBILICAL CORD BLOOD, STEM CELL BANKING Dr.Sharad Jain MD Blood Transfusion officer, & I/C Transfusion Medicine NSCB Medical College. Jabalpur.MP. Introduction: Every parent during childbirth DREAMS the
More informationBasic Science in Medicine
Medical Journal of th e Islamic Republic of Iran Volume 18 Number 3 Fall 1383 November 2004 Basic Science in Medicine ] EXPANSION OF HUMAN CORD BLOOD PRIMITIVE PROGENITORS IN SERUM-FREE MEDIA USING HUMAN
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 118 No 1208 ISSN 1175 8716 Private umbilical cord blood banking: a biological insurance of dubious future benefit! Michael Sullivan, Peter Browett, Nigel Patton In its
More informationUMBILICAL CORD BANKING. (formerly Unistem Biosciences Pvt.Ltd.)
UMBILICAL CORD BANKING (formerly Unistem Biosciences Pvt.Ltd.) INITIATIVES OF CELLUGEN BIOTECH PVT.LTD. (formerly Unistem Biosciences Pvt.Ltd.) UMBILICAL CORD BANKING UMBILICAL CORD STEM CELL THERAPY Stem
More informationSummary Basis for Regulatory Action
Date: June 13, 2013 Summary Basis for Regulatory Action From: Mohammad Heidaran, Ph.D., Chair of the Review Committee BLA/ STN#: 125432 Applicant Name: LifeSouth Community Blood Centers, Inc. Date of Submission:
More informationCord Blood: Research Progress and Future Promise
Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as
More information